Keros Therapeutics (KROS) Interest Coverage Ratio (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Interest Coverage Ratio came in at 0.3 in Q4 2025, up 99.49% YoY from 0.15 in Q4 2024, and up 87.38% on a QoQ basis from 2.37 in Q3 2025.
Keros Therapeutics (KROS) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Interest Coverage Ratio data on file, last reported at 0.3 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 99.49% year-over-year to 0.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.69 (up 100.24% YoY) and the FY2025 annual result came in at 0.69, up 149.07% from the prior year.
- Interest Coverage Ratio improved to 0.3 in Q4 2025, from 2.37 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 52.79 in Q4 2023 to a low of 4866.0 in Q4 2021.
- A 5-year average of 260.17 and a median of 0.88 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio tumbled 90921.37% — and 2025, when it surged 9276.05%.
- Tracing KROS's Interest Coverage Ratio over 5 years: stood at 4866.0 in 2021, then jumped by 96.92% to 150.05 in 2022, then soared by 135.18% to 52.79 in 2023, then plunged by 210.86% to 58.52 in 2024, then soared by 99.49% to 0.3 in 2025.
- The last three Interest Coverage Ratio figures came in at 0.3 (Q4 2025), 2.37 (Q3 2025), and 7.37 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.10 |
| Dec 31, 2025 | -0.30 |
| Sep 30, 2025 | -2.37 |
| Jun 30, 2025 | -7.37 |
| Mar 31, 2025 | 33.05 |
| Dec 31, 2024 | -58.52 |
| Sep 30, 2024 | -0.63 |
| Jun 30, 2024 | -0.93 |
| Mar 31, 2024 | -0.36 |
| Dec 31, 2023 | 52.79 |
| Sep 30, 2023 | -1.29 |
| Jun 30, 2023 | -0.83 |
| Mar 31, 2023 | -77.74 |
| Dec 31, 2022 | -150.05 |
| Sep 30, 2022 | -0.58 |
| Jun 30, 2022 | -1.01 |
| Mar 31, 2022 | -120.63 |
| Dec 31, 2021 | -4,866.00 |
| Sep 30, 2021 | -0.34 |
| Jun 30, 2021 | -0.22 |